Spreadsheet: 1c98f19a-65b9-43a2-a1c7-2da42fbe1991
Sheet: Sheet1

Observed Fusion Isoforms | Patient Number | FHCRC ID | Age at surgery | Stage | Grade | Histology | Chemotherapy | Tumor genomic status
[NAME], E2-C4 | 1 | 227740 | 49 | IIIC | 3 | serous | No prior chemo | breakpoint sequence by UHTS
[NAME], E2-C4 | 1 | 227747 | 49 | IIIC | 3 | serous | No prior chemo
[NAME], E2-C4 | 2 | 272381 | 88 | IIIC | 3 | serous | No prior chemo | copy-number variation by UHTS vs PBMC from same patient
 | 3 | 272146 | 48 | IIIC | 3 | serous | No prior chemo
E2-C3 | 3 | 272147 | 48 | IIIC | 3 | serous | No prior chemo
 | 4 | 299614 | 54 | IVA | 3 | serous | No prior chemo
 | 4 | 299615 | 54 | IVA | 3 | serous | No prior chemo
 | 5 | 299846 | 65 | IIIC | 3 | serous | No prior chemo
 | 5 | 299851 | 65 | IIIC | 3 | serous | No prior chemo
 | 6 | 201588 | 55 | IIIC | 3 | serous | No prior chemo
E2-C3 | 7 | 206704 | 46 | IIIC | 3 | serous | No prior chemo
 | 8 | 216132 | 81 | IIIC | 3 | serous | No prior chemo
 | 9 | 216924 | 59 | IIIC | 3 | serous | No prior chemo
 | 10 | 216947 | 42 | IIIC | 3 | serous | No prior chemo
 | 11 | 218319 | 63 | IVA | 3 | serous | No prior chemo
 | 12 | 218721 | 68 | IIIC | 3 | serous | No prior chemo
 | 13 | 219803 | 59 | IIIC | 1 | serous | No prior chemo
 | 14 | 220380 | 67 | IIIC | 3 | serous | No prior chemo
 | 15 | 221984 | 60 | IVA | 2 | serous | No prior chemo
[NAME], E2-C4 | 16 | 223065 | 76 | IVA | 3 | serous | Neoadjuvant chemo
E2-C3 | 17 | 225554 | 66 | IIIC | 3 | serous | No prior chemo
 | 18 | 240190 | 65 | IIIC | 3 | serous | No prior chemo
 | 19 | 243303 | 53 | IVA | 3 | serous | No prior chemo
 | 20 | 261405 | 44 | IIIC | 3 | serous | No prior chemo
 | 21 | 262471 | 59 | IIIC | 2 | serous | No prior chemo
E2-C5 | 22 | 265320 | 50 | IIIC | 3 | serous | No prior chemo
 | 23 | 265379 | 59 | IIIC | 3 | serous | Prior chemo for [NAME]
E2-C5 | 24 | 266562 | 60 | IIIC | 3 | serous | No prior chemo
[NAME], E2-C4 | 25 | 272397 | 70 | IIIC | 3 | serous | No prior chemo
 | 26 | 277602 | 51 | IIIC | 3 | serous | No prior chemo
 | 27 | 277627 | 75 | IIIC | 2 | serous | No prior chemo
 | 28 | 278002 | 46 | IIIC | 3 | serous | No prior chemo
 | 29 | 278051 | 57 | IVA | 3 | serous | No prior chemo
 | 30 | 278686 | 74 | IIIC | 3 | serous | No prior chemo
 | 31 | 291946 | 72 | IVA | 3 | serous | No prior chemo
 | 32 | 294157 | 67 | IIIB | 3 | serous | No prior chemo
 | 33 | 297951 | 62 | IIIA | 3 | serous | No prior chemo
 | 34 | 305266 | 87 | IIIC | 3 | serous | No prior chemo
 | 35 | 315158 | 50 | IVA | 3 | serous | No prior chemo
 | 36 | 348806 | 51 | IIIC | 3 | serous | No prior chemo
 | 37 | 500357 | 41 | IIIC | 3 | serous | No prior chemo
 | 38 | 500714 | 67 | IIIC | 3 | serous | No prior chemo
 | 39 | 500833 | 71 | IIIC | 3 | serous | No prior chemo
 | 40 | 501159 | 58 | IIIC | 3 | serous | No prior chemo
 | 41 | 501270 | 47 | IIIC | 3 | serous | No prior chemo
 | 42 | 501337 | 64 | IIIC | 3 | serous | No prior chemo
Observed Fusion Isoforms | Patient Number | BCCA ID | Age at surgery | Stage | Grade | Histology | Chemotherapy | Genomic status
 | 43 | IROC008 | 70 | IV | 3 | serous | No prior chemo
E2-C3 | 44 | IROC010 | 54 | IIB | 3 | papillary serous (some clear cell change) | No prior chemo
 | 45 | IROC013 | 67 | IIIC | 3 | serous (some squamous and undifferentiated) | No prior chemo
 | 46 | IROC014 | 52 | IV | 3 | serous | No prior chemo
 | 47 | IROC015 | 48 | IIIC | 3 | serous (papillary, some transitional) | No prior chemo
 | 48 | IROC018 | 63 | IIIC | 3 | serous | No prior chemo
 | 49 | IROC024 | 66 | IIIC | 3 | Serous | No prior chemo
 | 50 | [NAME] | 57 | IIIC | 3 | serous | No prior chemo
 | 51 | IROC042 | 68 | IIIC | 3 | serous/undifferentiated/ transitional | No prior chemo
 | 52 | IROC045 | 66 | IV | 3 | serous | No prior chemo
 | 53 | IROC046 | 54 | IIIC | 3 | serous | No prior chemo
 | 54 | IROC049 | 62 | IIC | 3 | Serous | No prior chemo
 | 55 | IROC051 | 44 | IIIC | 3 | serous | No prior chemo
 | 56 | IROC052 | 73 | IIIC | 3 | serous | No prior chemo
 | 57 | IROC057 | 70 | IIIC | 3 | serous | No prior chemo
 | 58 | IROC060 | 73 | T3c (AJCC) | 3 | Serous | No prior chemo
 | 59 | IROC063 | 83 | IIIC | 3 | serous | No prior chemo
 | 60 | [NAME] | 54 | IIIC/IV | 3 | serous | No prior chemo
 | 61 | IROC065 | 66 | IIIC | 3 | serous | No prior chemo
 | 62 | IROC067 | 72 | T3c (AJCC) | 3 | serous | No prior chemo
 | 63 | IROC069 | 59 | IIIC | 3 | serous | No prior chemo
 | 64 | IROC070 | 50 | IIIC | 3 | serous | No prior chemo
 | 65 | IROC072 | 65 | III | 3 | serous | No prior chemo
 | 66 | IROC078 | 50 | IIIC | 3 | serous (anaplastic) | No prior chemo
 | 67 | IROC080 | 78 | IIIC | 3 | Serous | No prior chemo
 |  | 4/6 or greater replicates positive at FHCRC, [NAME] sequence confirmed; genomic UHTS performed
 |  | 4/6 or greater replicates positive at FHCRC, [NAME] sequence confirmed.
 |  | 6/6 replicates positive at BCCA, [NAME] sequence confirmed.